News

Automotive
CCC
CCCF
CEL
CML / SELO
Cosmetics
DMF
Electrical Goods & Electronics
Fire Safety
Health Foods & Supplements
Household Appliances
IVDs
Medical Devices
Pharma & Biotech
RoHS
Special Equipment
Toys
Veterinary Drugs & Pet Foods
New NMPA guidelines for QMS

According to the Guide, the registrant of the medical device is responsible for implementing a suitable QMS for the product realization process.

March 11, 2026
New NMPA guidelines for QMS
New NMPA Measures for Random Medical Device Checking In-market

The NMPA announced new administrative measures designed to increase the post-market surveillance applicable to all registered medical devices sold in China.

March 9, 2026
New NMPA Measures for Random Medical Device Checking In-market
NMPA Essential Principles of Safety and Performance of Medical Devices

The principles describe the manufacturing requirements to ensure the medical device operates safely and performs as intended。

March 11, 2026
NMPA Essential Principles of Safety and Performance of Medical Devices
Cisema Webinar on Medical and Cosmetic Product Certification

AUSSENWIRTSCHAFT AUSTRIA and Cisema cohost the webinar to talk about the regulatory changes for both medical device and cosmetic industries.

March 29, 2022
Cisema Webinar on Medical and Cosmetic Product Certification
Overseas Marketing Approvals for Listing Medical Devices in Hong Kong
Overseas Marketing Approvals for Listing Medical Devices in Hong Kong

Medical devices approved by the NMPA or the Ministry of Food and Drug Safety of Korea can apply for the MDACS listing in Hong Kong within a trial period

March 9, 2026
Overseas Marketing Approvals for Listing Medical Devices in Hong Kong
China's Coronavirus Emergency Response for Urgently Needed Medical Devices

The prevention and control work were deployed as the top priority, and the registration process of some overseas medical products was expedited.

March 9, 2026
China's Coronavirus Emergency Response for Urgently Needed Medical Devices
China's Regulatory Pathway for Customized Medical Devices (CMDs)

NMPA provides a regulatory pathway for CMDs to meet the special clinical demands for medical institutions in China to treat designated patients.

March 9, 2026
China's Regulatory Pathway for Customized Medical Devices (CMDs)
From foreign- to China-made medical devices

Cisema will submit a proposal to the NMPA about the draft regulation before the consultation period ends on 31.03.2020. If you are interested to contribute, please provide your input to us

March 9, 2026
From foreign- to China-made medical devices
Cisema Webinar on Selling Medical Devices in China

On 4.3.2020, the China-Britain Business Council (CBBC) and Cisema held a webinar together to talk about the market, regulations and standards for overseas medical device products to enter the China market. Our business consultant, Anna King, provided an overview of the approval systems for NMPA registration in China and the recent implementation of urgent measures to expedite the approval procedures for medical and health products due to the CoronaVirus outbreak.Watch the recording of the webinar on Youtube.

March 29, 2022
Cisema Webinar on Selling Medical Devices in China
New product certification regulation from organization CCAP for automobile lighting, external plastic parts and break disks

New product certification regulation from organization CCAP for automobile lighting, external plastic parts and break disks

March 11, 2026
New product certification regulation from organization CCAP for automobile lighting, external plastic parts and break disks
Cisema Webinar on the Market Access of Cosmetic Products to China

The Israel Export Institute co-hosted a webinar together with Cisema to introduce the China administration bodies, regulations and standards for cosmetics.

March 29, 2022
Cisema Webinar on the Market Access of Cosmetic Products to China
Filing of Imported Non-Special Use Cosmetics with Beijing MPA

Currently, there are 14 municipalities with the capacity to file non-special purpose cosmetics, and Cisema can guide you through the MPA filing process.

March 9, 2026
Filing of Imported Non-Special Use Cosmetics with Beijing MPA
Chinese certification authorities published measures to support the containment of the corona virus outbreak

On 04.02.2020, the authorities SAMR (State Administration for Market Regulation) and CNCA (China National Certification Administration) published in their Notice No 9/2020 general support measures to contain the corona virus outbreak. Chinese certification organizations are bound by these requirements.The measures include:

  • Processes are to be optimized so that personal contact is reduced as much as possible.
  • Factory inspections by a Chinese certification organization, which must be postponed due to the current situation, must be communicated openly with the affected certificate holders in order to fix an alternative date by mutual agreement. Or other solutions are agreed upon.
  • Applications for factories that have stopped production due to the outbreak and are unable to complete an inspection of their manufacturing plant in order to obtain the desired certification (e.g. CCC - China Compulsory Certification), but are subject to a time limit for this, may not be suspended. The necessary inspection should be completed at the latest 3 months after the official announcement that the state of emergency has been lifted.
March 11, 2026
Chinese certification authorities published measures to support the containment of the corona virus outbreak
China's Recent Measures for the Urgent Approval of Medical and Health Products Amid Coronavirus Outbreak

The Ministry of Commerce announced the list of intermediary services and administrative examinations and approvals for import and export of goods in China.

March 9, 2026
China's Recent Measures for the Urgent Approval of Medical and Health Products Amid Coronavirus Outbreak
Implementation of Hong Kong-Registered Pharmaceutical Products and Common Medical Devices in China's Greater Bay Area
Implementation of Hong Kong-Registered Pharmaceutical Products and Common Medical Devices in China's Greater Bay Area

Cisema has the capability to help you comply with Hong Kong MDACS requirements and expand your businesses in the Greater Bay Area

Implementation of Hong Kong-Registered Pharmaceutical Products and Common Medical Devices in China's Greater Bay Area
Cross Border E-Commerce (CBEC): 24 New Zones and New List of Retail Imported Commodities

On 27.12.2019, the China Ministry of Finance, General Administration for Market Regulation and 11 other ministries announced (No.96-2019) the List of Cross-border E-commerce Retail Imported Commodities (2019 edition) covering a total of 1413 types of commodities. The list added roughly 100 types of goods, and removed 8 types from the 2018 edition. According to China Customs, products on the list are exempted from submitting related import licenses. When entering the special trade zone, the commodites on the list will be checked by customs in accordance with the standard procedures for clearing commodities, but will then be exempted when leaving the special trade zone. The updated list came into effect on 01.01.2020.On 24.12.2019, the Chinese State Council announced (No.36-2019) that the State Taxation Administration had approved the establishment of 24 pilot cross-border e-commerce (CBEC) zones - in addition to the 35 pilot CBEC zones that have previously been established - and introduced exemptions on value-added tax and consumption tax for retail and exported goods. The approved document announces the initial plan of how the trial zones will be constructed and replicated across China. More detailed information regarding tax rebates, government support, and international logistic services are expected to follow after this announcement.Please do contact us to know if your products are involved.

March 9, 2026
Cross Border E-Commerce (CBEC): 24 New Zones and New List of Retail Imported Commodities
Plastic Microbeads to be banned from Daily Chemical Articles

On 06.11.2019, the China NDRC (National Development and Reform Commission) announced (No.20-2019) the prohibition of daily chemical articles containing plastic microbeads for production after December 31, 2020, and for sale after December 31, 2022.Microbeads are small plastic particles, mostly included in cosmetic and cleaning products, and are known to cause water pollution to the marine and freshwater environments. Currently, 14 states have already taken action towards the ban on microbeads. Although the details of the ban for production and sales in China is still subject to further refinement, brands and manufacturers are expected to reformulate their products containing microbeads, while some have already replaced microbeads with natural abrasives as an alternative in daily chemical articles.The announcement (No.20-2019) is based on the Industrial Structure Adjustment Guidance Catalogue (2019 Edition) that was approved at the 2nd committee meeting on 27.08.2019, and has replaced the 2011 version since 01.01.2020.

March 9, 2026
Plastic Microbeads to be banned from Daily Chemical Articles
New Clinical Trial Exemption Lists for Medical Devices and IVDs

On 20.12.2019, the China NMPA (National Medical Products Administration) announced (No.91-2019) that it would add 148 medical devices and 23 in-vitro diagnostic reagents to the clinical trial exemption list, as well as to revise the names and descriptions of 48 medical devices and 4 in-vitro diagnostic reagents. Medical devices and in-vitro diagnostic reagents on the clinical trial exemption list won’t require completion of clinical trials in order to achieve NMPA certification.This new clinical trial exemption list is effective since the date of announcement on 20th December.Feel free to contact us if you would like to know what products were included in the clinical trial exemption list for medical devices, and the clinical trial exemption list for IVDs.

March 13, 2026
New Clinical Trial Exemption Lists for Medical Devices and IVDs
Clinical Evaluation Reports can be Created Based on Real-World Data

The China NMPA (National Medical Products Administration) is seeking input on whether real world data can be used for Clinical Evaluation Reports. This is a potentially very significant development and Cisema will submit a proposal to the NMPA before the consultation period ends on 13 January 2020.

March 9, 2026
Clinical Evaluation Reports can be Created Based on Real-World Data
SAMR publishes the Health Food Naming Guideline 2019

On November 12, 2019, the SAMR published the Health Food Naming Guideline 2019 for the naming rule of China registered and filed health food.

SAMR publishes the Health Food Naming Guideline 2019

Get in Touch with Our Consultants

And discover how we can support you.

Angebot anfordern